Shareholders are to sue drug firm for not disclosing adverse reactions even though number wasn’t significantBMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d2011 (Published 29 March 2011) Cite this as: BMJ 2011;342:d2011
- Clare Dyer
The US Supreme Court has unanimously cleared the way for investors in a company that makes an over the counter cold remedy to go ahead with a lawsuit against it for failing to disclose reports that the product caused adverse effects, even though the number of reports fell short of statistical significance.
Shares in the US based Matrixx Initiatives plummeted in 2004 after media reports that some users of its Zicam nasal spray, whose active ingredient was zinc gluconate, had lost their sense of smell. Investors filed a class action alleging securities fraud, on the basis that the company had failed to disclose …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial